BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tu CL, Wang YL, Hu TM, Hsu LF. Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development? BioDrugs 2019;33:437-46. [PMID: 31111423 DOI: 10.1007/s40259-019-00357-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Schreiber S, Yamamoto K, Muniz R, Iwura T. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab. Pharmacol Res Perspect 2020;8:e00604. [PMID: 32500668 DOI: 10.1002/prp2.604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Webster CJ, Woollett GR. Comment on "Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?". BioDrugs 2019;33:581-2. [PMID: 31372960 DOI: 10.1007/s40259-019-00372-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Kurki P, Kang HN, Ekman N, Knezevic I, Weise M, Wolff-Holz E. Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. BioDrugs 2022. [PMID: 35596890 DOI: 10.1007/s40259-022-00533-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Song F, Zheng X, Wang Y, Chow SC, Sun H. Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References. AAPS J 2021;24:3. [PMID: 34850298 DOI: 10.1208/s12248-021-00658-x] [Reference Citation Analysis]
5 Webster CJ, George KL, Woollett GR. Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance. BioDrugs 2021;35:379-87. [PMID: 34143406 DOI: 10.1007/s40259-021-00488-5] [Reference Citation Analysis]
6 Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 2021;81:1859-79. [PMID: 34705255 DOI: 10.1007/s40265-021-01610-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ebbers HC, Fehrmann B, Ottosen M, Hvorslev N, Høier P, Hwang JW, Chung J, Lim HT, Lee S, Hong J, Rezk MF. Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars. BioDrugs 2020;34:225-33. [PMID: 31925703 DOI: 10.1007/s40259-019-00402-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Niazi SK. Biosimilars: Harmonizing the Approval Guidelines. Biologics 2022;2:171-95. [DOI: 10.3390/biologics2030014] [Reference Citation Analysis]